Abstract: The present disclosure provides a method for producing a radio frequency (RF) pulse for use in magnetic resonance. The steps of the method include providing a computer system and a set of RF input parameters. The computer system then generates an optimal phase surface by iteratively updating an initial RF pulse profile based at least in part on the set of RF input parameters. The optimal phase surface contains a set of iteratively generated RF pulse profiles with various characteristics, such as bandwidths or selectivity. The steps of the method further include selecting an RF pulse profile with the computer system based on a search on the optimal phase surface, which can be implemented with the help of an index file. The search can be performed using an artificial intelligence algorithm, and can retrieve the shortest pulse profile that satisfies user input parameters or requirements.

Abstract: The present disclosure provides a method for producing a radio frequency (RF) pulse for use in magnetic resonance. The steps of the method include providing a computer system and a set of RF input parameters. The computer system then generates an optimal phase surface by iteratively updating an initial RF pulse profile based at least in part on the set of RF input parameters. The optimal phase surface contains a set of iteratively generated RF pulse profiles with various characteristics, such as bandwidths or selectivity. The steps of the method further include selecting an RF pulse profile with the computer system based on a search on the optimal phase surface, which can be implemented with the help of an index file. The search can be performed using an artificial intelligence algorithm, and can retrieve the shortest pulse profile that satisfies user input parameters or requirements.

Abstract: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment.

Abstract: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment.

Abstract: This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment.